Streetbeat News

Stock Prices

PFE

Pfizer's Phase 3 CROWN trial shows that 60% of patients with ALK-positive advanced lung cancer treated with LORBRENA remain alive without disease progression after five years, compared to 8% with XALKORI. The study also shows an 81% reduction in the risk of progression or death and a 94% reduction in brain metastases progression with LORBRENA.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:04 pm

BTDR

Bitdeer Technologies Group (NASDAQ:BTDR) announced a private placement financing deal with Tether International Limited, involving the issuance of 18,587,360 Class A shares and a warrant to purchase up to 5 million additional shares at $10 per share. The transaction generated $100 million in gross proceeds and could provide an additional $50 million if the warrant is fully exercised.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:02 pm

BNOX

Bionomics shares are trading higher following the announcement of a private placement of up to $70 million.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:02 pm

INDA

India's Gross Domestic Product (GDP) for Q4 grew by 7.8% year-over-year, surpassing the estimated 6.7% and slightly below the prior quarter's 8.4%.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:02 pm

ACLX

In the past three months, 11 analysts have published ratings on Arcellx (NASDAQ:ACLX), with the majority being bullish. The average 12-month price target has increased to $81.09, with a high estimate of $87.00 and a low estimate of $70.00. Recent analyst actions include upgrades and maintained ratings, reflecting positive sentiment towards the company's financial performance and growth prospects.

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 12:01 pm

XOMA

Analysts have provided a range of ratings for XOMA (NASDAQ:XOMA) over the past three months, with the majority being bullish. The average 12-month price target has declined by 9.19% to $67.2. XOMA has shown significant revenue growth but faces challenges with high debt levels.

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 12:00 pm

EGAN

eGain Corporation's board has approved a $20 million increase to its stock buyback program, signaling confidence in the company's future prospects and potentially boosting shareholder value.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:00 pm

ALLO

Analysts have provided mixed ratings for Allogene Therapeutics (NASDAQ:ALLO) over the past three months, with a recent positive shift in the average 12-month price target. The company's financials show challenges, including a significant decline in revenue growth and negative net margins, but it maintains strong ROE and ROA.

Portfolio Pulse from Benzinga Insights

May 31, 2024 | 12:00 pm

DOOO

BRP shares are trading lower after the company reduced its FY25 guidance.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:53 am

ESTC

Elastic shares are trading higher following a Q4 earnings beat.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 11:52 am